

Table 2 ONGOING TRIALS OF PREVENTIVE HIV/AIDS VACCINES WORLDWIDE (APRIL 2008)

Protocol #	Start Date	Sponsor, Funder, Developer	Trial Site(s)	# of Participants	Vaccine(s)	Clade
PHASE III						
RV 144	Oct-03	USMHRP, MoPH Thailand, Aventis, Vaxgen	Thailand	16,402	Prime: canarypox viral vector with <i>env</i> and <i>gag-pol</i> Boost: Env protein (gp120 subunits)	B A/E
TEST-OF-CONCEPT						
The two trials that follow, HVTN 503 and 502, stopped enrollment and immunizations, September 2007. Follow-up and data collection continue. For more information visit: http://avac.org/vax_update.htm .						
HVTN 503 (Phambili)	Feb-07	SAAVI, HVTN	South Africa	801	Adenovirus vector with <i>gag, pol, nef</i>	B
HVTN 502/ Merck 023 (Step study)	Dec-04	DAIDS, HVTN, Merck	US, Canada, Peru, Dominican Republic, Haiti, Puerto Rico, Australia, Brazil, Jamaica	3,000	Adenovirus vector with <i>gag, pol, nef</i>	B
PHASE II						
IAVI A002	Nov-05	Children's Hospital of Pennsylvania, Columbus Children's Research Center, Indian Council of Medical Research, National AIDS Control Organization, Targeted Genetics Corp.	South Africa, Uganda, Zambia	91	AAV2 (adeno-associated virus type 2) vector with <i>gag, pol, ΔRT</i>	C
HVTN 204	Sep-05	DAIDS, HVTN, VRC, Vical, GenVec	US, Brazil, South Africa, Haiti, Jamaica	480	Prime: DNA vaccine with <i>gag, pol, nef + env</i> Boost: Adenovirus vector with <i>gag, pol + env</i>	A, B, C
ANRS VAC 18	Sep-04	ANRS, Aventis	France	132	5 lipopeptides with CTL epitopes from <i>gag, nef, pol</i>	B
PHASE I / II						
EV 03/ANRS Vac20	June-07	European Commission, ANRS	UK, Germany, Switzerland, France	140	Prime: DNA vaccine with <i>env</i> plus <i>gag, pol, nef</i> Boost: NYVAC-C	C
HIVIS 03	Dec-06	MUCHS, Karolinska Institute, SMI, Vecura, USMHRP	Tanzania	60	Prime: HIVIS DNA with <i>env, gag, rev, RT</i> Boost: MVA-CMDR with <i>env, gag, pol</i>	A, B, C A, E
RV 172	May-06	NIH, USMHRP, VRC	Kenya, Uganda, Tanzania	324	Prime: DNA vaccine with <i>gag, pol, nef + env</i> Boost: Adenovirus vector with <i>gag, pol + env</i>	B A, B, C
PHASE I						
N/A	Apr-08	IPCAVD, Brigham and Women's Hospital, Beth Israel Deaconess Medical Center, Crucell	US	48	Recombinant adenovirus serotype 26 (rAd26) vaccine	A
HVTN 070	Oct-07	NIAID, HVTN, UPenn/Wyeth	US	120	PENNVAX-B alone, in combination with IL-12, or with 2 different doses of IL-15	B
HVTN 072	Aug-07	NIAID, HVTN, VRC	US	17	DNA and Adenovirus 5 or 35 vectors, all with <i>env</i> in varying prime-boost combinations	A
HVTN 071 [As of Sept 07 enrollment and vaccinations have been discontinued]	Jul-07	NIAID, HVTN, Merck	US	35	Adenovirus 5 vector with <i>gag, pol, nef</i>	B
DVP-1	May-07	St. Jude's Children's Research Hospital	US	20	Prime-boost regimen with <i>PolyEnv, EnvPro, EnvDNA</i>	A, B, C, D, E
VRC 012	May-07	NIAID, VRC	US	35	HIV-1 adenovirus vector vaccine VRC-HIVADV027-00VP: dose escalation and prime-boost with an HIV-1 adenovirus vector vaccine, VRC-HIVADV038-00-VP	A
HVTN 067	Apr-07	NIAID, HVTN, Pharmexa-Epimmune, Bavarian Nordic	US	108	DNA Vaccine EP-1233 and recombinant MVA-HIV polytope vaccine MVA-mBN32, separately and in a combined prime-boost regimen	B A, B, C, D, E, G

Protocol #	Start Date	Sponsor, Funder, Developer	Trial Site(s)	# of Participants	Vaccine(s)	Clade
PHASE I						
DHO-0586	Oct-06	ADARC, IAVI	US	8	ADMVA with <i>env/gag-pol, nef-tat</i>	C
HPTN 027	Oct-06	Makerere University, Johns Hopkins University	Uganda	50	Canarypox viral vector with <i>env</i> and <i>gag-pol</i>	B
C86P1	Sep-06	SGUL, Richmond Pharmacology, Novartis Vaccines	UK	31	Prime: HIV gp140 with LTK63 Boost: HIV gp140 with MF59	B
VRC 011	Apr-06	NIAID, VRC	US	60	DNA vaccine with <i>gag, pol, nef + env</i> or Adenovirus vector with <i>gag, pol + env</i>	A, B, C
HVTN 065	Apr-06	NIAID, HVTN, GeoVax	US	120	Prime: DNA plasmid with <i>gag, pro, RT, env, tat, rev, vpu</i> Boost: MVA vector with <i>gag, pol, env</i>	B
HVRF-380-131004	Mar-06	Moscow Institute of Immunology, Russian Federation Ministry of Education and Science	Russian Federation	15	VICHREPOL with polyoxidonium adjuvant	B
IAVI D001	Feb-06	IAVI, Therion	India	32	Modified vaccinia Ankara (MVA) viral vector with <i>env, gag, tat-rev, nef-RT</i>	C
HIVIS 02	Jan-06	Karolinska Institute, Swedish Institute for Infectious Disease Control, USMHRP	Sweden	38	Modified vaccinia Ankara (MVA) viral vector with <i>env, gag, and pol</i> to volunteers from HIVIS 01	A, E
RV 158	Nov-05	USMHRP, NIH	US, Thailand	48	Modified vaccinia Ankara (MVA) viral vector with gp160, <i>gag</i> and <i>pol</i>	A, E
HVTN 063	Sep-05	DAIDS, HVTN, Wyeth	US, Brazil	120	Prime: Genevax Gag-2692 +/- IL-15 DNA Boost: Genevax Gag-2692 + IL-12 DNA or IL-15 DNA	B
HVTN 060	Aug-05	DAIDS, HVTN, Wyeth	US, Thailand	144	Prime: Genevax Gag-2692 +/- IL-12 DNA adjuvant Boost: DNA plasmids with <i>gag</i> or RC529-SE and GM-CSF with <i>env, gag, nef</i>	B
<i>EnvDNA</i>	May-05	St. Jude's Children's Research Hospital	US	6	Recombinant HIV-1 multi-envelope DNA plasmid vaccine with <i>env</i>	A, B, C, D, E
VRC 008	Apr-05	NIAID, VRC	US	40	Prime: DNA vaccine with <i>gag, pol, nef + env</i> Boost: Adenovirus vector with <i>gag, pol + env</i>	B A, B, C
N/A	Mar-05	Changchun BCHT, Guangxi CDC	China	49	Prime: DNA vaccine Boost: recombinant adenovirus vector	C
HIVIS 01	Feb-05	Karolinska Institute, Swedish Institute for Infectious Disease Control, Vecura	Sweden	40	Intramuscular or intradermal injections of plasmid DNA with HIV genes <i>env, rev, gag, and RT</i> .	A, B, C
EuroVacc 02	Feb-05	EU, Imperial College London, UK MRC Clinical Trials Unit, EuroVacc	UK, Switzerland	40	Vaccinia vector with <i>gag, pol, nef, env</i>	C
RV 156 A	Nov-04	NIAID, HVTN, VRC, USMHRP, Makerere U.	Uganda	30	VRC-HIVADV014-00-VP alone or as a boost to VRC-HIVDNA009-00-VP	A, B, C
IAVI C002	Jan-05	IAVI, ADARC, University of Rochester	US	48	Modified vaccinia Ankara (MVA) viral vector with <i>env/gag-pol, nef-tat</i>	C
HVTN 050/ Merck 018	Jan-04	NIAID, HVTN, Merck	Thailand, Brazil, Haiti, Puerto Rico, South Africa, US, Malawi, Peru	435	Adenovirus vector with <i>gag</i>	B
<i>EnvPro</i>	Jun-03	St. Jude's Children's Research Hospital	US	9	Recombinant Purified HIV-1 Envelope Protein Vaccine	D

ABL: Advanced BioScience Laboratories
ADARC: Aaron Diamond AIDS Research Center
ANRS: Agence Nationale de Recherches sur le Sida (France)
DAIDS: Division of AIDS
HVTN: HIV Vaccine Trials Network
IAVI: International AIDS Vaccine Initiative

IPCAVD: Integrated Preclinical/Clinical AIDS Vaccine Development
MoPH: Ministry of Public Health
MUCHS: Muhimbili University College of Health Sciences
NIAID: National Institute of Allergy and Infectious Diseases
NIH: National Institutes of Health
SAAVI: South African AIDS Vaccine Initiative

SGUL: St. George's, University of London
SMI: Swedish Institute for Infectious Disease Control
UK MRC: United Kingdom Medical Research Council
USMHRP: United States Military HIV Research Program
VRC: Vaccine Research Center
ZEHRP: Zambia Emory HIV Research Project

For an updated list of trials visit www.avac.org/research.htm.